PubMed13 Apr 2026Diabetes care● 6/10i Hepatic Events Prevention by Antihyperglycemic Therapies and Intervention Comparisons in Type 2 Diabetes: The HEPATIC-T2DM Network Meta-analysis.
Passos PRC, Motta R, Oliveira Costa Filho V, Noronha MM, Venâncio RC et al.
GLP-1 receptor agonists showed the lowest risk of hepatic decompensation versus all other diabetes drug classes (HRs 0.16-0.91), while thiazolidinediones had the lowest hepatocellular carcinoma risk and SGLT2 inhibitors the lowest cirrhosis risk. Network meta-analysis of 46 observational studies including 7.1 million adults with type 2 diabetes. This provides the first comprehensive liver safety ranking across all major diabetes drug classes, potentially informing prescribing in patients with existing liver disease risk. All evidence is observational, limiting causal conclusions.
Strategic Signal
This liver safety hierarchy could influence US and EU diabetes guidelines for patients with NAFLD or cirrhosis risk, where prescriber choice between GLP-1s and SGLT2s often depends on available safety data. Novo Nordisk and Eli Lilly gain potential messaging advantages for GLP-1s in hepatic decompensation prevention, while broader SGLT2 class benefits in cirrhosis may support continued dual therapy approaches. Regulatory authorities may request liver-specific outcome trials to confirm these observational associations.
Original Abstract
BACKGROUND: Type 2 diabetes mellitus (T2DM) amplifies liver disease burden, yet the comparative hepatic effects of antidiabetic drugs remain poorly defined. PURPOSE: To compare associations between antidiabetic drug classes and major adverse liver outcomes (MALOs) in adults with T2DM. DATA SOURCES: PubMed, EMBASE, and Cochrane Central Register of Controlled Trials were searched from December 1946 through 23 August 2025. STUDY SELECTION: Studies enrolling adults with T2DM that evaluated associations between antidiabetic drug classes with regard to MALOs were included. DATA EXTRACTION: Data were extracted on study characteristics, drug exposures, and MALOs. DATA SYNTHESIS: A three-level Bayesian network meta-analysis with study- and database-level random effects was performed. Outcomes are reported as hazard ratios (HRs) and ranked using the surface under the cumulative ranking curve. Forty-six observational studies (N = 7,124,845) were included. Thiazolidinediones were least associated with hepatocellular carcinoma incidence and significantly lower than DPP-4 inhibitors (HR 0.50), GLP-1RAs (HR 0.72), insulin (HR 0.20), and sulfonylureas (HR 0.69). For decompensation (composite), GLP-1RAs were associated with the lowest hazard compared with all other classes (HRs 0.16-0.91; all significant). SGLT2 inhibitors were least associated with cirrhosis (HR 0.66 vs. DPP-4 inhibitors; HR 0.66 vs. GLP-1RAs). GLP-1RAs were least associated with variceal bleeding and hepatic encephalopathy, whereas SGLT2 inhibitors were least associated with liver-related mortality. LIMITATIONS: All included studies were observational, precluding causal inference. CONCLUSIONS: Liver-specific risk reduction is not uniform across antihyperglycemic drug classes. Randomized trials are needed to determine whether these associations reflect true drug effects.